Hetero Labs Limited entered into a binding agreement to acquire Manufacturing Facility at Vemgal from GlaxoSmithKline Pharmaceuticals Limited (BSE:500660) for INR 1800 million on March 31, 2021. The transaction is subject to approval from shareholders and board of GlaxoSmithKline Pharmaceuticals Limited and regulatory and statutory approvals. As of March 30, 2021, board of GlaxoSmithKline Pharmaceuticals Limited has approved the transaction. The transaction is expected to be completed by September 30, 2021